What Itraconazole 200 Treats: Main Uses and Benefits

Itraconazole 200 is commonly used to help with symptomatic support across several domains where fungal infections may create noticeable physiological strain. Its role is applied in addressing the infection to support long-term patient comfort.

The medication is considered relevant for easing the risk associated with several conditions, including deep-seated systemic fungal infections like Blastomycosis, Histoplasmosis, and Aspergillosis; chronic infections of the skin and nails, such as onychomycosis; and specific mucosal yeast infections.

The therapeutic benefit is relevant for supporting stability during difficult episodes. “This medication may assist patients with coping more steadily with difficult episodes.”

Management of Primary Therapeutic Domains

This medicine is applied in clinical settings that involve acute or unstable symptom patterns from deep-seated fungal infections. It may assist with managing symptom clusters that may become intense or disruptive, including persistent fever and symptoms related to systemic imbalance. It is also generally used across conditions presenting with systemic or localized discomfort, such as when physical damage and deterioration of the nails interferes with daily comfort. This supportive relief helps maintain a sense of stability when symptoms are more noticeable.

---

Quick Fact: May assist with Persistent Fungal Symptoms

It is also commonly used in high-risk patient groups, like immunocompromised individuals, where its role is applied during phases of increased distress or discomfort to prevent the onset of severe, opportunistic fungal diseases. This use in prophylaxis supports the provision of relief when symptoms interfere with routine activities.

Regulatory References

1. DailyMed (NIH) label information

Who Can and Cannot Use Itraconazole 200

Itraconazole 200 eligibility is strictly defined by regulatory criteria, primarily permitting Adult Patients.

---

Contraindicated Populations

The medicine is contraindicated and must not be used by patients with known hypersensitivity to itraconazole or its excipients. A critical restriction applies to patients with ventricular dysfunction such as Congestive Heart Failure (CHF) or a history of CHF; this is an absolute exclusion for indications like onychomycosis. Use is also forbidden when co-administered with a specific list of CYP3A4-metabolized medicines that are formally classified as contraindicated.

---

Age and Conditional Restrictions

Use is not recommended in the paediatric population (under 18 years) as safety and efficacy have not been established. Similarly, use in older adults is not recommended unless the benefit outweighs the risk, and dose selection must account for age-related decline in organ function.

Pregnancy is contraindicated for non-life-threatening fungal infections, and women of childbearing potential must use effective contraceptive precautions during therapy. Furthermore, patients with active liver disease or significantly elevated liver enzymes are strongly discouraged from use unless the benefit is critical. Patients with renal impairment require caution and close monitoring due to limited data.

Itraconazole 200 is officially documented as a strong inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme and the P-glycoprotein (P-gp) drug transporter. This dual inhibition establishes a pharmacokinetic interaction pattern that leads to increased systemic plasma concentrations of numerous co-administered medicines that are substrates for these systems.

Contraindicated Drug Combinations

Co-administration with Itraconazole 200 is formally contraindicated for specific medicines where increased exposure can result in severe or life-threatening reactions. These include certain Antiarrhythmics (such as Dofetilide and Quinidine), HMG-CoA Reductase Inhibitors (such as Lovastatin and Simvastatin), and Ergot Alkaloids (such as Ergotamine). The prohibition on co-use with Colchicine is explicitly noted for patients with pre-existing renal or hepatic impairment.

Exposure-Modifying Substances

Medicines that are strong CYP3A4 inducers, such as Rifampicin or the herbal product St. John's Wort, must be avoided as they significantly reduce the plasma concentration of Itraconazole, potentially leading to sub-therapeutic systemic exposure.

Timing and Food Requirements

The oral bioavailability of Itraconazole capsules is maximized when administered immediately after a full meal. Furthermore, co-administration with gastric acid secretion suppressors, such as H2-receptor antagonists or antacids, can reduce the absorption of Itraconazole. Regulatory rules state that antacids must be separated from Itraconazole capsules by at least 2 hours. Population-specific considerations also note that pharmacokinetic parameters are altered in patients with hepatic or renal impairment.

Targeting Fungal Cell Membrane Synthesis

Itraconazole functions as a triazole antifungal by selectively inhibiting the fungal enzyme lanosterol 14 alpha-demethylase (CYP51). This enzyme is crucial for the conversion of lanosterol into ergosterol, the primary stabilizing sterol required for fungal cell membranes. The drug’s structure binds to the heme iron in the active site of the fungal CYP51, establishing a key mechanistic prerequisite for antifungal activity.

---

Disruption of Fungal Cell Structure and Function

Blocking ergosterol synthesis leads to a direct structural and functional compromise of the fungal cell membrane. This results in the accumulation of toxic intermediate sterols and increased membrane permeability, causing the leakage of essential cellular components and impairing the function of membrane-bound enzymes. This cellular disruption impairs the ability of the fungal cell to maintain osmotic stability and execute division processes.

---

Selective Action and Physiological Consequence

Itraconazole exhibits high binding affinity for the fungal CYP51 enzyme compared to structurally similar mammalian P450 enzymes. This selective targeting concentrates the molecular disturbance within the fungal organism, which is essential for determining the scope of the resulting physiological consequences.

Itraconazole 200 mg is an oral capsule formulation intended for systemic administration. The drug's usage is governed by strict administration protocols designed to ensure sufficient bioavailability and tissue accumulation, as detailed in regulatory documents.

Administration and Timing

The primary requirement for the capsule is that it must be taken immediately after a full meal to facilitate maximal absorption. The capsule must be swallowed whole and should not be crushed, opened, or chewed. Absorption is dependent on adequate stomach acidity; therefore, if a patient is also taking acid-reducing medication, the official label suggests administering the capsule with an acidic beverage (such as non-diet cola) to maintain systemic exposure.

Official Dosing Regimens

Dosing is structured based on the type of infection being addressed. For widespread systemic infections, treatment typically begins with a loading dose of 200 mg three times daily for the first 3 days. This is followed by a maintenance dose of 200 mg once or twice daily, with the maximum dose generally not exceeding 400 mg per day. Doses greater than 200 mg daily are required to be administered in divided doses.

For conditions like onychomycosis, an intermittent or pulse dosing model is often utilized: 200 mg twice daily for 7 days, followed by a 21-day drug-free interval. This cycle is typically repeated two to three times. The regulatory basis also specifies that the capsule and oral solution formulations are not bioequivalent and must not be interchanged on a milligram-for-milligram basis.

Research Evidence / Overview of Studies for Itraconazole 200

---

Evidence for Use in Deep-Seated Systemic Fungal Infections

Research on Itraconazole 200 has been applied in studies examining patient-reported experiences related to deep-seated fungal infections, such as Blastomycosis and Histoplasmosis. The research generally involves prospective, open-label, non-randomized cohort trials. The outcomes measured include the resolution of symptoms and the elimination of the fungus from tissue cultures (mycological cure).

Studies report patterns observed in research exploring outcomes related to patients diagnosed with mild-to-moderate forms of these endemic mycoses. What remains uncertain is the availability of large, head-to-head, randomized controlled trials (RCTs) against treatments used for the most severe forms. The results apply only to the populations studied, which predominantly involve patients with non-critical disease, and certainty remains low regarding long-term outcomes.

---

Evidence for Preventing Opportunistic Fungal Disease

The medicine was evaluated in a research context exploring its potential role in preventing the onset of severe fungal diseases in highly vulnerable individuals. These studies were high-quality, randomized, placebo-controlled, double-blind trials (RCTs). Findings describe patterns observed in the studies where the use of Itraconazole was associated with a lower incidence rate of certain opportunistic fungal infections compared to placebo. However, the results apply only to the populations studied (high-risk patient groups) and follow-up durations were limited in certain prophylaxis settings.

---

Evidence for Superficial Fungal Infections (Onychomycosis)

The research base for fungal infections of the nails (onychomycosis) is founded on multiple Randomized Controlled Trials (RCTs) and systematic reviews. The outcomes measured included mycological cure and clinical cure. The trials required long-term follow-up observation periods of nine to twelve months post-treatment to allow for assessment of the final outcome after new nail growth. Subgroup findings are uncertain regarding patients with significant underlying conditions, as these individuals were often excluded from the main research.

Common questions about Itraconazole 200 (FAQ)

---

Q: How quickly does Itraconazole 200 start working for a fungal infection?

Official information indicates that the medicine is typically absorbed into the bloodstream, with peak concentrations observed within a few hours. However, achieving steady-state drug concentrations—the consistent levels required for treatment—generally takes about 15 days of continuous dosing. The full therapeutic effect is linked to the drug's accumulation in the affected tissue over time.

---

Q: Is it common to feel tired while taking Itraconazole 200?

Official safety data indicates that tiredness or fatigue is listed among the possible side effects reported by patients using this medicine. This information is found within the drug's authorized regulatory documentation.

---

Q: Is it necessary to have blood tests while on Itraconazole 200?

Laboratory testing may be necessary during treatment. Regulatory guidelines describe that if signs or symptoms consistent with liver disease develop, liver function testing is required. Furthermore, laboratory monitoring may be necessary to confirm the fungal infection has resolved before stopping the medicine.

---

Q: Does Itraconazole 200 interact with birth control pills?

Itraconazole is documented as a strong CYP3A4 inhibitor, which means it can increase the concentration of other medicines that use the same pathway, including certain components of hormonal birth control (like progestogens). This increased concentration may lead to altered drug effects or potentially increase the risk of side effects for the co-administered medication.

---

Q: Is Itraconazole 200 used to treat athlete's foot?

The FDA-approved indications for Itraconazole capsules are deep systemic infections and nail fungus (onychomycosis). However, the medicine is cited in certain medical compendia for use in some superficial skin infections caused by dermatophytes, such as tinea pedis (athlete's foot).

---

Q: Is there a maximum time a person can take Itraconazole 200?

The duration of treatment is specific to the type of infection being addressed. Regulatory documents specify that therapy can range from weeks to over a year (e.g., 6 to 12 months for certain systemic infections). The duration is intended to continue until clinical and laboratory evaluations suggest the fungal infection has subsided.

---

Q: What kind of research exists on Itraconazole 200 and resistance?

The official drug label contains information regarding antifungal resistance. It notes that fungal isolates with decreased susceptibility (reduced effectiveness) to Itraconazole have been found both in laboratory settings and from patients who have undergone prolonged therapy with the medicine.

---

Q: Do the side effects of Itraconazole 200 usually go away after treatment ends?

The timing for side effects to resolve aligns with the rate at which the drug is eliminated from the body. Pharmacokinetic data shows that the drug concentration in the bloodstream decreases rapidly within one to two weeks after the last dose, although it can persist in tissues like the skin and nails for a longer period.

---

Q: Are there different trade names for Itraconazole 200?

Yes. Itraconazole is the generic name of the active drug. It is listed as being available under various trade names, including Sporanox, Onmel, and Tolsura, as referenced in authoritative drug compendia.

---

Q: What is the risk of skin rash with Itraconazole 200?

Regulatory adverse reaction reports indicate that skin rash is a possible side effect of Itraconazole. This includes the potential for developing urticaria, commonly referred to as hives.

---

Q: Does Itraconazole 200 contain lactose or gluten?

Official labeling, which lists all inactive components (excipients), states that the capsules contain ingredients such as sucrose (sugar), maize starch, and purified water. The full list of inactive ingredients for the specific formulation prescribed is available for review for patients with specific dietary restrictions.

---

Q: Can I take Itraconazole 200 if I am breastfeeding?

Regulatory sources on lactation indicate that the active ingredient is excreted into human milk, although typically only in small amounts. Official health authority guidance generally notes that use of the drug or breastfeeding is not recommended during therapy.

---

Q: Is Itraconazole 200 the same as fluconazole?

No, Itraconazole and fluconazole are two different antifungal medicines, even though they both belong to the same pharmacological class, the triazole antifungals. Regulatory documents describe that they have different approved uses, side effect profiles, and dosing requirements.

---

Q: What is the main reason doctors prescribe Itraconazole 200?

The FDA-approved uses for Itraconazole capsules include the treatment of certain severe systemic fungal infections such as histoplasmosis and blastomycosis. It is also approved for treating fungal infections of the toenails, known as onychomycosis.

---

Q: What are the signs of a severe reaction to Itraconazole 200?

As described in the regulatory warnings, signs of a severe reaction related to the liver may include yellowing of the skin or eyes, unusual tiredness, dark urine, or pale stools. Signs of congestive heart failure may include trouble breathing, sudden weight gain, or swelling in the limbs.

---

Q: Is it safe to drive or operate machinery while taking Itraconazole 200?

The official patient information notes that the medicine can sometimes cause side effects like dizziness or blurred/double vision. The patient information provided in the regulatory labeling includes a caution against driving or operating machinery if these visual disturbances or dizziness occur.

---

Q: Is Itraconazole 200 used for yeast infections as well as mold infections?

Yes, Itraconazole is recognized for its broad-spectrum activity. Regulatory indications include treatment for certain types of candidiasis (which is caused by yeast) as well as infections caused by molds and other fungi (e.g., Blastomycosis, Histoplasmosis).

How to Store and Dispose of Itraconazole 200

Official regulatory guidelines strictly define the conditions for storing, protecting, and discarding Itraconazole 200 capsules to ensure product stability and safety.

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, typically 15, C to 25, C (59, F to 77, F).
Protection	Keep the capsules protected from excess heat, moisture, and light.
Packaging	Keep the medication in its original container and ensure the container is tightly closed.
Safety	Keep the medication strictly out of the reach of children and pets.

Disposal Instructions

Do not dispose of unused or expired Itraconazole capsules by flushing them down the toilet or pouring them down a drain. The official recommendation is to utilize a local drug take-back program. If a take-back program is unavailable, mix the medicine with an unappealing substance, seal it in a plastic bag or container, and place it in the household trash. This procedure prevents environmental contamination and misuse.